NCT03932201Active, not recruiting
Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
Observational Study Evaluating Effectiveness and Safety of Real-World Treatment With Damoctocog Alfa Pegol in Previously Treated Patients With Hemophilia A
Source: ClinicalTrials.gov · Last updated 1 Jul 2026
Brief summary (registry, in English)
The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 371 (actual)
- First submitted
- 18 Apr 2019
- Start date
- 21 Oct 2019
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Bayer
- Diseases
- Haemophilia
- NCT number
- NCT03932201
What you commit to
- Study type: Observational
- Participants enrolled: 371
- From 21 Oct 2019 to the primary completion date, 31 Dec 2026
- 29 sites in 20 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent participation in an investigational program with interventions outside of routine clinical practice.
Other illness
- Diagnosis of any other bleeding/coagulation disorder other than hemophilia A.
Other
- Contra-indications according to the local marketing authorization.
- Patient on immune tolerance induction (ITI) treatment at the time of enrollment.
Who the study is looking for
- Diagnosis of hemophilia A.
- Patients previously treated for Hemophilia A.
- Patients without previous history of inhibitors or patients with previous history of inhibitors on standard prophylaxis therapy for at least 1 year prior to study entry.
- No current evidence of FVIII inhibitor or clinical suspicion of FVIII inhibitor.
- Initiation of or currently on damoctocog alfa pegol with any kind of treatment modality (on-demand, prophylaxis, or intermittent prophylaxis).
- Signed informed consent/assent.
Sex: All · Does not accept healthy volunteers
Sites (29)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Many locations Coordinator of this site? Confirm its status | Multiple Locations | United Arab Emirates | Unknown status |
| Many locations Coordinator of this site? Confirm its status | Multiple Locations | Belgium | Unknown status |
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Brazil | Unknown status |
| Many locations Coordinator of this site? Confirm its status | Multiple Locations | Canada | Unknown status |
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Switzerland | Unknown status |
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Colombia | Unknown status |
| Many locations Coordinator of this site? Confirm its status | Multiple Locations | Germany | Unknown status |
| Many locations Coordinator of this site? Confirm its status | Multiple Locations | Denmark | Unknown status |
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Spain | Unknown status |
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Greece | Unknown status |
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Italy | Unknown status |
| Many locations Coordinator of this site? Confirm its status | Multiple Locations | Japan | Unknown status |
| Many locations Coordinator of this site? Confirm its status | Multiple Locations | Kuwait | Unknown status |
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Netherlands | Unknown status |
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Norway | Unknown status |
| Many locations Coordinator of this site? Confirm its status | Multiple Locations | Saudi Arabia | Unknown status |
| Many locations Coordinator of this site? Confirm its status | Multiple Locations | Sweden | Unknown status |
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Slovenia | Unknown status |
| Many Locations Coordinator of this site? Confirm its status | Multiple Locations | Taiwan | Unknown status |
| University of Colorado Hemophilia and Thrombosis Center Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
| University California Davis Coordinator of this site? Confirm its status | Davis | United States | Unknown status |
| East Carolina University - Brody School of Medicine Coordinator of this site? Confirm its status | Greenville | United States | Unknown status |
| Orthopaedic Hospital DBA Orthopaedic Institute for Children Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| Regents of University of Minnesota Coordinator of this site? Confirm its status | Minneapolis | United States | Unknown status |
| South Alabama Medical Science Foundation Coordinator of this site? Confirm its status | Mobile | United States | Unknown status |
| Tulane University Coordinator of this site? Confirm its status | New Orleans | United States | Unknown status |
| The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders Coordinator of this site? Confirm its status | Orange | United States | Unknown status |
| Banner MD Anderson Cancer Center Coordinator of this site? Confirm its status | Phoenix | United States | Unknown status |
| Georgetown University Coordinator of this site? Confirm its status | Washington D.C. | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.